Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells

Blood

Volumn 90, Issue 1, 1997, Pages 279-289

  Urashima, Mitsuyoshi ^b   Teoh, Gerrard ^b   Chauhan, Dharminder ^b   Hoshi, Yasutaka ^b   Ogata, Atsushi ^b   Treon, Steven P ^b   Schlossman, Robert L ^b   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 6; PROTEIN P21; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

EID: 0031010127     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.279     Document Type: Article

References (47)

1. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF2/IL6 for human multiple myeloma. Nature 332:83, 1988
2. Anderson KC, Jones RC, Morimoto C, Leavitt P, Barut B: Response of purified myeloma cells to hematopoietic growth factors. Blood 73:1915, 1989
3. Klein B, Zhang XZ-G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:512, 1989
4. Barut B, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohrbacher A, Fingeroth J, Anderson KC: Role of interleukin-6 in the growth of myeloma-derived cell lines. Leuk Res 16:951, 1992
5. Hitzler J, Martinez-Valdez H, Bergsagel D, Minden MD: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-MY1-7 established from patients with advanced stage of the disease. Blood 78:1996, 1991
6. Levy Y, Tsapis A, Brouet JC: Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 88:696, 1991
7. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266, 1989
8. Zhang XG, Gaillard JP, Robillard N, Lu AY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654, 1994
9. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Ziao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84:3063, 1994
10. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A: Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85:487, 1995
11. Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Takatsuki K: Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 86:1939, 1995
12. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I: The role of interleukin-1 and tumor necrosis factor-α in human multiple myeloma. Br J Haematol 74:424, 1990
13. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC: Transforming growth factor β1: Differential effects on multiple myeloma versus normal B cells. Blood 87:1928, 1996
14. Schwab M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao J, Princler GL, Kung H: Disruption by interferon-α of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterogeneous down-regulation of IL-6 receptor α-and β-chains. J Clin Invest 94:2317, 1994
15. Portier M, Zhang X-G, Caron E, Lu Z-Y, Bataille R, Klein B: γ-Interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 81:3076, 1993
16. Palumbo A, Bataglio S, Napoli P, Omede P, Fusaro A, Bruno B, Boccadoro M, Pileri A: Recombinant interferon-γ inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 86:726, 1994
17. Palumbo A, Bruno B, Boccadoro M, Piled A: Interferon-γ in multiple myeloma. Leuk Lymphoma 18:215, 1995
18. Westendorff JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek D: CD40 expression in malignant plasma cells: Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 152:117, 1994
19. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903, 1995
20. Ogata A, Nishimoto N, Hisma Y, Yoshizaki K, Kishimoto T: Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 84:3040, 1994
21. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82:3712, 1993
22. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991
23. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248, 1995
24. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gp130. Blood 86:1243, 1995
25. Urashima M, Ogata A, Chauhan D, Vidriales MA, Teoh G, Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC: Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 88:2219, 1996
26. Hirama T, Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841, 1995
27. Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T: Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 22:1989, 1992
28. Urashima M, Hoshi Y, Sugimoto Y, Kaihara C, Matsuzaki M, Chauhan D, Ogata A, Teoh G, DeCaprio JA, Anderson KC: A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16 INK4A/p15INK4B tumor suppressor and immunoglobulin heavy chain genes: TGF β/IL-7 inhibitory signaling mechanism. Leukemia 10:1576, 1996
29. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato J-Y: D type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066, 1994
30. Mazars G-R, Portier M, Zhang X-G, Jourdan M, Bataille R, Theillet C, Klein B: Mutations of the p53 gene in human myeloma cell lines. Oncogene 7:1015, 1992
31. Chin YE, Kitagawa M, Su W-CS, You Z-H, Iwamoto Y, Fu X-Y: Cell growth arrest and induction of cyclin dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science 272:719, 1996
32. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Volgelstein B, Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935, 1995
33. Zeng Y-X, El-Deiry WS: Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12:1557, 1996
34. Jung J-M, Bruner JM, Ruan S, Langford LA, Kyritisis AP, Kobayashi T, Levin VA, Zhang W: Increased levels of p21WAF1/ Cip1 in human brain tumors. Oncogene 11:2021, 1995
35. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB: High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1:1051, 1995
36. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrim S, Bertacca G, Chella A, Merlo G, Angeletti CA, Palma PD, Bevilacqua G: p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12:1319, 1996
37. Shiohara M, El-deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen D-L, Vogelstein B, Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781, 1994
38. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Lee YY, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266, 1995
39. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675, 1995
40. Wang J, Walsh K: Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273:359, 1996
41. Polyak K, Waldman T, He T-C, Kinzler KW, Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10:1945, 1996
42. Attadi LD, Lowe SW, Brugarolas J, Jacks T: Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 15:3693, 1996
43. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for irradiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
44. Yuh Y-S, Thompson EB: Glucocorticoid effect on oncogene/ growth gene expression in human T lymphoblastic cell line CCRF-CEM. J Biol Chem 264:10904, 1989
45. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, Verma IM, Evans RM: Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62:1217, 1990
46. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M: Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62:1205, 1990
47. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Pomta H, Herrlich P: Antitumor promotion and antiinflammation: Down-regulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189, 1990